☆ 4.7 Review

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

EUROPEAN JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai et al.

Summary: In highly glycolytic tumors, regulatory T (Treg) cells have higher PD-1 expression compared to effector T cells. Under low-glucose conditions, Treg cells actively absorb lactic acid through monocarboxylate transporter 1 (MCT1), promoting the expression of PD-1, while PD-1 expression by effector T cells is dampened. PD-1 blockade invigorates PD-1-expressing Treg cells, resulting in treatment failure.

CANCER CELL (2022)

Add to Collection

Review Oncology

PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis

Hongsheng Deng et al.

Summary: To date, there is no approved biomarker for predicting pathological response in neoadjuvant PD-(L)1 blockades treated early-stage NSCLC. However, high PD-L1 expression and high TMB are associated with higher rates of MPR and pCR. The cutoff value of 50% demonstrates better prediction efficacy for MPR than 1%.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan et al.

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

David R. Spigel et al.

Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Hallmarks of Cancer: New Dimensions

Douglas Hanahan

Summary: The concept of the hallmarks of cancer is a tool for simplifying the complexity of cancer phenotypes and genotypes into basic principles. This article proposes phenotypic plasticity and disrupted differentiation as distinct hallmark capabilities, and discusses nonmutational epigenetic reprogramming and polymorphic microbiomes as enabling characteristics. Additionally, the importance of senescent cells in the tumor microenvironment is highlighted. The integrative concept of the hallmarks of cancer helps in understanding the mechanisms of cancer development and applying that knowledge to cancer medicine.

CANCER DISCOVERY (2022)

Add to Collection

Editorial Material Oncology

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study

L. Paz-Ares et al.

Summary: This study evaluated the efficacy of adjuvant pembrolizumab compared to placebo in patients with completely resected early-stage non-small cell lung cancer. The results showed that adjuvant pembrolizumab significantly improved disease-free survival in the overall population, but did not reach statistical significance in the PD-L1 expression >= 50% population. Adverse events were more common in the pembrolizumab group compared to the placebo group.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Original Research Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

Mariona Riudavets et al.

Summary: This study aimed to investigate the efficacy of Durvalumab in patients with stage III unresectable NSCLC harboring driver genomic alterations (dGA). The results showed limited activity of Durvalumab in patients with EGFR/BRAF mutations and ALK rearrangements, but no activity in those with KRAS mutations. Larger prospective studies are needed to confirm these findings.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nazli Dizman et al.

Summary: Adding a live bacterial product to an immunotherapy combination can enhance the clinical outcome in patients with metastatic renal cell carcinoma, showing longer progression-free survival and higher response rate.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie et al.

Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Meeting Abstract Oncology

A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)

M. H. H. Schuler et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study

J. Spicer et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions

Lian Narunsky-Haziza et al.

Summary: This study comprehensively characterizes the cancer mycobiome in cancer patients and finds low abundances of fungi in various human cancers. The composition of fungal communities differs among cancer types and they are frequently associated with cancer cells and macrophages spatially. Comparisons with bacterial and immune communities reveal co-occurring bi-domain ecologies and distinct immune responses. The tissue and plasma mycobiomes show prognostic and diagnostic capabilities even in early stage cancers, and synergistic predictive performance with bacterial communities.

CELL (2022)

Add to Collection

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O'Brien et al.

Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.

LANCET ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft et al.

Summary: This study examined the use of neoadjuvant atezolizumab in patients with resectable non-small cell lung cancer. It found that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but further studies are needed to confirm these findings.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Roberto Ferrara et al.

Summary: T-cell immunosenescence is observed in up to 28% of patients with aNSCLC, correlating with lack of benefit from ICI treatment but not from PCT.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Respiratory System

The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap

Pei Yee Tiew et al.

Summary: The airway microbiome composition in COPD and bronchiectasis is relatively comparable, with certain microbial dominance associated with disease severity and exacerbations. However, the role of the microbiome in bronchiectasis-COPD overlap remains understudied.

CLINICAL RESPIRATORY JOURNAL (2021)

Add to Collection

Article Oncology

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial

Corinne Faivre-Finn et al.

Summary: In the Phase 3, placebo-controlled PACIFIC trial, consolidative durvalumab after chemoradiotherapy showed significant improvements in overall survival and progression-free survival for patients with unresectable, stage III NSCLC, with consistent benefits observed approximately 4 years after treatment. Durvalumab demonstrated durable benefits with a higher 4-year survival rate and progression-free survival rate compared to placebo.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Liver metastases inhibit immunotherapy efficacy

Katherine E. Lindblad et al.

Summary: Liver metastases can cause resistance to immunotherapy by drawing tumor antigen-specific CD8(+) T cells into the liver, leading to a systemic 'immune desert' that is unable to control tumor burden.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy

Ithar Gataa et al.

Summary: High-TIL was associated with favorable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

Add to Collection

Article Immunology

Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients

Claire Germain et al.

Summary: The presence of high TLS-B cell density in NSCLC tumors is associated with better clinical outcomes and more specific CD4(+) T cell responses. High TLS-B cell density can counterbalance the negative impact of high Treg density on patient survival, suggesting a central role for B cells in determining protective T cell responses in NSCLC patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

S. Kilickap et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Article Oncology

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

D. Carbone et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Article Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki et al.

Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.

LANCET ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

R. Dziadziuszko et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Marta Casarrubios et al.

Summary: The study aimed to characterize the T-cell receptor (TCR) repertoire as a potential predictive biomarker for pathologic response to immunotherapy in locally advanced nonsmall cell lung cancer (NSCLC). The analysis revealed a positive association between an uneven TCR repertoire in tissue samples and complete pathologic response (CPR) after surgery. Furthermore, top 1% TCR clones in diagnostic biopsies showed potential as predictive biomarkers for CPR, outperforming PD-L1 tumor proportion score (TPS) and tumor mutational burden (TMB).

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Laura Mezquita et al.

Summary: In patients with aNSCLC receiving ICI treatment, high dNLR at baseline (B) correlated with worse PFS/OS, while high dNLR at cycle 2 (C2) was associated with even poorer outcomes. Persistently high dNLR (B+C2) was linked to early ICI failure, suggesting immature neutrophils may play a key role in ICI resistance.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Oncology

Mutational status of main driver genes influences the prognosis of stage I-III lung adenocarcinoma patients underwent radical surgery

Hongliang Liao et al.

Summary: The study investigated the influence of main driver gene mutations and clinicopathological factors on overall survival in 447 stage I-III lung adenocarcinoma (LUAD) patients who underwent radical surgery. Mutational status of TP53, EGFR, and STK11, as well as T and N grading, were found to significantly impact patient prognosis.

TRANSLATIONAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke et al.

Summary: The presence of mature tertiary lymphoid structures is associated with improved response to immunotherapy in cancer patients, predicting objective response rates, progression-free survival, and overall survival. These findings support the potential use of TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.

NATURE CANCER (2021)

Add to Collection

Article Oncology

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer

Ilaria Alborelli et al.

JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Oncology

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer

Jiajia Zhang et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

Annikka Weissferdt et al.

CLINICAL LUNG CANCER (2020)

Add to Collection

Review Immunology

Tumor Immunology and Tumor Evolution: Intertwined Histories

Jerome Galon et al.

IMMUNITY (2020)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Alexandre Reuben et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Oncology

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

Jose Carlos Benitez et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu et al.

LANCET ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

B. Besse et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Joshua E. Reuss et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Immunology

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Alex D. Waldman et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Everett J. Moding et al.

NATURE CANCER (2020)

Add to Collection

Article Oncology

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

Simon Papillon-Cavanagh et al.

ESMO OPEN (2020)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer

Mohammad Jafarnejad et al.

AAPS JOURNAL (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

E. J. Aguilar et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Editorial Material Oncology

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

S. Peters et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Valsamo Anagnostou et al.

CANCER RESEARCH (2019)

Add to Collection

Article Genetics & Heredity

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert M. Samstein et al.

NATURE GENETICS (2019)

Add to Collection

Article Critical Care Medicine

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer

Yoshikane Yamauchi et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Oncology

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Sarah B. Goldberg et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC

A. Lisberg et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Laura Mezquita et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer

Qingzhu Jia et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Oncology

Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab

Rajiv Raja et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer

Yuki Iijima et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

Hironori Uruga et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Article Oncology

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Samra Turajlic et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Oncology

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review

Robert Brody et al.

LUNG CANCER (2017)

Add to Collection

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Yonit Lavin et al.

CELL (2017)

Add to Collection

Article Oncology

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

M-S. Tsao et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Danay Saavedra et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis

Jincui Gu et al.

MOLECULAR AND CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Shifts in subsets of CD8+T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study

Oscar Okwudiri Onyema et al.

BMC CANCER (2015)

Add to Collection

Review Oncology

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

A. Wang et al.

EJSO (2015)

Add to Collection

Article Oncology

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

Moon-Young Kim et al.

LUNG CANCER (2015)

Add to Collection

Review Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Edward B. Garon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Critical Care Medicine

Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer

Claire Germain et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)

Add to Collection

Article Oncology

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers

Jamie E. Chaft et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Microenvironmental regulation of tumor progression and metastasis

Daniela F. Quail et al.

NATURE MEDICINE (2013)

Add to Collection

Article Oncology

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer

Enriqueta Felip et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial

DC Betticher et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.